| 翻訳と辞書 |
IMP321
IMP321 is a large molecule cancer drug being developed by the clinical stage biotechnology company Prima BioMed (Nasdaq: PBMD). The drug is Prima's lead compound.
IMP321 is soluble version of the immune checkpoint molecule LAG3, used to increase an immune response to tumours. The drug is administered by subcutaneous injection. IMP321 has two intended clinical settings, 'low dose' (for example 250 µg) as adjuvant to cancer vaccines and 'high dose' (such as 12 injections of 6 mg each) as first-line 'chemo-immunotherapy', that is, combined with standard chemotherapy. IMP321 has been in Phase II clinical testing. The product has been shown to be non-immunogenic, that is, no anti-IMP321 antibodies have been detected in clinical trials. Currently the main indication for the drug is metastatic breast cancer.
== Background ==
IMP321 is a 200 kDA soluble dimeric recombinant fusion protein of the extracellular portion of LAG3 with immunoglobulin, designed to activate antigen presenting cells. LAG3 is expressed on various cells in the immune system including activated T cells, Natural Killer cells (NK cells), B cells and dendritic cells, being a ligand for MHC class II molecules. On T cells LAG-3 is an inhibitory receptor. However, on dendritic cells LAG-3 is an activator, causing increased antigen presentation to cytotoxic CD8+ T cells when it binds to MHC Class II. IMP321 is designed to harness this activation capacity as a 'chemo-immunotherapeutic', increasing antigen presentation in the wake of tumor debris created by chemotherapy.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「IMP321」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|